160948-33-4

Basic information

• Product Name: 2-Pyrimidinamine, 4-methyl-5-nitro-6-(phenylmethoxy)-
• Synonyms: 2-Pyrimidinamine, 4-methyl-5-nitro-6-(phenylmethoxy)-;4-(benzyloxy)-6-methyl-5-nitropyrimidin-2-amine(WXC06551);4-(BENZYLOXY)-6-METHYL-5-NITROPYRIMIDIN-2-AMINE
• CAS NO: 160948-33-4
• Molecular Formula: C₁₂H₁₂N₄O₃
• Molecular Weight: 260.25
• Mol File: 160948-33-4.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 518.1±60.0 °C(Predicted)
• Appearance: /
• Density: 1.362±0.06 g/cm3(Predicted)
• PKA: 2.69±0.10(Predicted)
• CAS DataBase Reference: 2-Pyrimidinamine, 4-methyl-5-nitro-6-(phenylmethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyrimidinamine, 4-methyl-5-nitro-6-(phenylmethoxy)-(160948-33-4)
• EPA Substance Registry System: 2-Pyrimidinamine, 4-methyl-5-nitro-6-(phenylmethoxy)-(160948-33-4)

Safety Data

• Hazardous Substances Data: 160948-33-4(Hazardous Substances Data)

Upstream product

• 13162-24-8 2-amino-4-chloro-5-nitro-6-methylpyrimidine 
• 100-51-6 benzyl alcohol 
• 299916-90-8 2-N-acetylamino-6-methyl-5-nitropyrimidin-4-one 
• 20194-18-7 sodium phenyl-methanolate 
• 4214-85-1 2-amino-6-methyl-5-nitro-4(3H)-oxopyrimidine 

Downstream Products

• 299916-95-3 4-benzyloxy-2-[(di-N,N-methylamino)methylene]amino-6-[2-(N,N-dimethylamino)vinyl]-5-nitropyrimidine 
• 299916-87-3 6-O-benzyl-9-deaza-2-N-formylguanine 
• 299916-98-6 2-amino-4-benzyloxy-5-N-benzyloxymethylpyrrolo[3,2-d]pyrimidine 
• 299917-00-3 6-O-benzyl-7-N-benzyloxymethyl-9-bromo-9-deazaguanine 
• 364046-15-1 2-di-N,N-benzyl-6-O-benzyl-7-N-benzyloxymethyl-9-bromo-9-deazaguanine 

Relevant articles and documents

Addition of lithiated 9-deazapurine derivatives to a carbohydrate cyclic imine: Convergent synthesis of the aza-C-nucleoside immucillins

Means have been developed for the synthesis and addition of 9-deaza-9-lithiopurine derivatives to the carbohydrate-derived cyclic imine 6 in facile convergent syntheses of biologically active aza-C-nucleosides.

Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines

The present invention provides 8-substituted O6 -benzylguanines of the formula STR1 wherein R1, R2, and R3 are as defined in the specification, and 4(6)-substituted 2-amino-5-nitro-6(4)-benzyloxypyrimidine, and 4(6)-substituted 2-amino-5-nitroso-6(4)-benzyloxypyrimidine derivatives which have been found to be effective AGT inactivators, as well as pharmaceutical compositions comprising such derivatives along with a pharmaceutically acceptable carrier. The present invention further provides a method of enhancing the chemotherapeutic treatment of tumor cells in a mammal with an antineoplastic alkylating agent which causes cytotoxic lesions at the O6 -position of guanine, by administering to a mammal an effective amount of one of the aforesaid derivatives, 2,4-diamino-6-benzyloxy-s-triazine, 5-substituted 2,4-diamino-6-benzyloxypyrimidines, or 8-aza-O6 -benzylguanine, and administering to the mammal an effective amount of an antineoplastic alkylating agent which causes cytotoxic lesions at the O6 -position of guanine.